By modifying existing #psychedelics, improved medicines can be created to treat a wide range of #MentalHealth disorders. See how Enveric is leveraging the Psybrary, to enable the development of next-generation psychedelics. https://t.co/XRzkDHT29J $ENVB
The patent application & claimed drug candidates fall into Enveric's EVM201 second-generation, #psychedelic-derived drug development program, with an initial target indication of #cancer-related distress and the potential to be expanded into additional #MentalHealth indications.
We are pleased to announce the expansion of our portfolio of drug development candidates and filing of a provisional patent application based on new discoveries by Enveric. Learn more here: https://t.co/ajAKpoiHvE $ENVB
Enveric's new provisional patent application describes more than 100 novel individual molecules and, if the broadest claims are allowed, could protect more than 10,000 possible new drug development candidates. https://t.co/ajAKpoiHvE $ENVB
We are pleased to participate in the Maxim 2022 Virtual Growth Conference being held next week on March 28th to March 30th. Register here to attend: https://t.co/oAmgbGUbZ1 $ENVB
Enveric's Chief Medical Officer, Dr. Bob Dagher has over 20 years of clinical research experience within #neuroscience in academia and industry organizations. Dr. Dagher shares why he wanted to join the Enveric team. $ENVB
Enveric's patent applications aim to expand opportunities for novel therapeutics to address a broad range of psychiatric and neurological disorders. Learn more here: https://t.co/mZiwkoZO84 $ENVB
The published PCT patent applications protecting Enveric’s novel tryptamine-derived molecules, as well as the respective Written Opinion of the International Searching Authority for each application, are available for review on the @WIPO website. $ENVB
We are pleased to announce that Enveric's first four Patent Cooperation Treaty (PCT) applications for the tryptamine family of novel molecules have been published by the World Intellectual Property Organization (@WIPO). Learn more: https://t.co/mZiwkoZO84 $ENVB
Radiodermatitis (RD) is a common side effect of radiation therapy that can lead to complications including discomfort, treatment delays and diminished quality of life. Enveric is developing EV102, a #CBD-based product, to help those suffering from RD https://t.co/TVzfrj3a0s $ENVB
Imagine $IXHL scooping up $MCUR, $MYCO, $NM, and $ENVB (combined market caps ~$50 million).
IXHL would suddenly have the leading clinics network, iSTRYM, a premier novel molecule-developer, and very prospective smoking cessation R&D.
And it would add nearly $50 million in cash.
Today at 11:45am ET, our CEO, Dr. Joseph Tucker will participate in the Q1 Virtual Investor Summit. Register here to attend: https://t.co/O0CdVOQjaf $ENVB
Members of the @Benzinga#Psychedelics Advisory Council will share their expertise through a series of articles, opinion pieces, live conversations at the Benzinga Psychedelics Capital Conference, and quotes on relevant news. $ENVB
We are pleased to announce Dr. Joseph Tucker has joined the @Benzinga#Psychedelics Advisory Council, which is composed of key thought leaders in the psychedelics space. https://t.co/HDQZzfCgsU $ENVB
"We stand in solidarity with the people of Ukraine and are hoping for a peaceful resolution. We are grateful for the opportunity to play a small role in giving back to those impacted by the conflict.” Vijay Talwar, Wish CEO.
How will we do that?
THREAD:
Enveric's robust IP portfolio of #psychedelic-inspired molecules positions us to achieve global patent protection to potentially cover millions of novel pharmaceutical candidates. Learn about our tryptamine-based derivative molecules here: https://t.co/jZVQKYGU4t $ENVB